GeneInCell

NAMs are changing how new drugs are developed. We discuss organoids, tissue chips, and AI-based tools, along with the growing FDA and NIH push toward more human-relevant methods that can improve prediction, reduce reliance on animal models, and help bring safer treatments forward faster.

Can we grow new kidneys from stem cells? In this episode, we explore how scientists are using pluripotent stem cells to create kidney organoids that mimic early kidney development. We discuss how these mini-organs help study kidney disease, test new drugs, and move us closer to future regenerative therapies for kidney failure.

What really happens to your cells under stress, in space, and during space travel? In this episode, we zoom in on the physiological, cellular, and molecular levels to uncover how zero gravity affects them.

What does it take to grow a beating human heart in the lab? This episode explores cardiac organoids—self-organizing heart tissues derived from human stem cells that contract, respond to drugs, and model human heart disease. We unpack how iPSCs are guided into cardiac lineages, how electrical and mechanical cues drive maturation, and why these beating mini-hearts are transforming drug safety testing, disease modeling, and the future of regenerative cardiology.

In this episode, we explore the AI revolution in healthcare and what 2026 could look like—from smarter diagnostics and personalized treatments to automation that reshapes clinical workflows. We break down the key innovations, emerging trends, and real-world impact of AI on patients, clinicians, and the healthcare system.

Synthetic biology is turning cells into programmable factories, sensors, and therapies. In this episode, we explore how DNA can be engineered like code to build smarter medicines, sustainable biomaterials, and living devices—and what it will take to move these innovations from the lab to the real world.

How do you give “mini-brains” a bloodstream? This episode explores vascular brain organoids—cerebral organoids engineered with endothelial cells, pericytes, and astrocytes to form BBB-like barriers, improve oxygen/nutrient delivery, and accelerate neuronal maturation. We cover why perfusion matters for MEA activity and drug testing, how microvessels enable neurovascular-coupling studies, and what it will take to scale these tissues for translational neuroscience.

Brain organoids are self-organizing “mini-brains” grown from human stem cells that recapitulate key aspects of early neural development. They fire neural networks on MEAs, model neurodevelopmental and neurodegenerative diseases, and offer human-relevant platforms for drug discovery, circuit mapping, and studying brain evolution—while raising important questions about maturity, reproducibility, and ethics.

Grow a “mini-gut” from stem cells—fast. This episode maps the journey from pluripotent cells to functional intestinal organoids, covering key signals (Activin A, Wnt3a/R-spondin, EGF), culture formats (3D domes vs. monolayers), and core readouts (TEER, permeability, metabolism). We highlight use cases in disease modeling and drug testing.

Discover how 3D intestinal organoids—mini-gut tissues grown from stem cells—are transforming preclinical drug testing. We break down how these models capture human barrier function, absorption, metabolism, and host–microbiome interactions better than animal systems, enabling smarter toxicity profiling and efficacy screening. From patient-derived organoids for precision medicine to organoid-on-chip platforms, we cover practical workflows, readouts (TEER, imaging, omics), and what it takes to translate in-vitro hits into clinical candidates.

DNA as code, cells as computers. We explore how binary models of genomes reveal mutational logic, why evolution mirrors open-source development, and how this lens powers DNA data storage, biomolecular logic gates, and smarter synthetic biology.

Silicon is hitting its limits—and our data keeps exploding. In this episode, we explore DNA as a radical new archive: a medium with hyper-dense capacity and millennia-scale stability that doesn’t need power to preserve information. We unpack the workflow—encoding 1s and 0s into A, T, C, and G; writing short DNA oligos; and reading them back with sequencing plus robust error-correction.

Explore the shift from standard Cas9 nuclease—which makes double-strand breaks—to precision tools like Cas9 nickases (single-strand “nicks”) and dead Cas9 (binding without cutting). We break down how these variants reduce off-target indels and enable safer editing and gene regulation (CRISPRi/a, base/prime editor scaffolds) for high-fidelity genome engineering.

From stem cells to therapies, this episode dives into the world of human liver organoids—how iPSCs are guided into functional “mini-livers,” the bioengineering tricks that mature them, and the breakthroughs they enable in disease modeling, drug screening, and precision hepatology. In this short episode, we unpack what’s real, what’s next, and how organoids are accelerating the path to regenerative treatments.

How PiggyBac moves DNA in—and out—without scars. We cover transposase mechanics (TTAA-site integration and footprint-free excision), large cargo delivery (tens to ~100 kb), and why it’s popular for iPSCs, stable cell lines, and cell therapies.

A quick tour of next-gen models that add functional vascularization and immune cells to boost physiological relevance. And strategies (self-assembly, pre-patterning) to build perfusable microvascular networks for real maturation.Educational only; not medical advice.

How lab-grown mini-retinas model human vision. In this episode, we show how iPSC-derived retinal organoids form layered photoreceptors, enable gene-editing tests (CRISPR, ASOs), and accelerate drug screening for inherited retinal diseases. Clear takeaways, visuals, and translational notes for bench and clinic. Educational only; not medical advice.

How FOXP3-defined Tregs prevent autoimmunity and shape therapy. We trace the discoveries by Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi, unpack Treg biology and assays, and explore translational angles—from autoimmune disease and transplantation to cancer immunotherapy and engineered Tregs. Educational content only; not medical advice.

How do you turn genes on with CRISPR—without making a single cut? This episode breaks down dCas9-based activators (VP64, p300, SAM, VPR, SunTag), guide design near promoters/enhancers. We compare strengths, limits, and off-target risks. Clear takeaways on assays (qPCR, RNA-seq, ATAC-seq, reporter readouts), durability, and safety considerations for translational work. Educational only; not medical advice.

In this episode, we explore how turning off defective genes is becoming a crucial aspect of modern medicine. Educational only; not medical advice.

Dive into the fascinating world of antisense oligonucleotides (ASOs) with this insightful podcast series. Explore the journey from genetic sequencing to groundbreaking therapeutic applications, uncovering how these innovative molecules are transforming the treatment of genetic disorders and beyond. Hosted by experts from GeneInCell, this series blends cutting-edge science with real-world impact, offering a deep dive into the future of precision medicine. Tune in to stay ahead in the evolution of human health!Educational content only; not medical advice.

How modern AI is rewiring the life-science stack—from target discovery to first-in-human. This episode unpacks foundation models for proteins/RNAs, generative chemistry, AI-guided ADMET/PK, phenotypic screening on organoids with high-content imaging, multi-omics integration, and self-driving labs with active learning. We compare what’s hype vs. real, walk through validation loops (prospective wet-lab tests, reproducibility, bias control), and map the path to clinic and regulation. Case studies highlight wins and failures—and where AI can truly compress timelines and costs.Educational content only; not medical advice

This episode spotlights Spaceflight-Associated Neuro-Ocular Syndrome (SANS)—a major risk where microgravity-driven fluid shifts raise eye/brain pressure, leading to optic nerve swelling and vision changes. Beyond SANS, we examine the full spectrum of space eye hazards: corneal abrasions from lunar/planetary dust, chemical burns, infections, and radiation effects. Educational content only; not medical advice.

We map the transition of science into companies in the USA. Hear how funding cycles, NIH/SBIR grants, talent pipelines, universities, CDMOs, and clinical-trial access shape each hub. Educational only; not investment advice.

What does space do to the body—and how can it advance medicine? We break down microgravity’s risks (fluid shifts/SANS, bone loss, muscle atrophy, cardiovascular deconditioning, immune dysregulation, radiation exposure) , then explore benefits for biotech: protein crystallization, stem-cell growth, organoids/tissue engineering, and drug discovery. Clear takeaways for space medicine and Earth health. Educational only; not medical advice.

Sources trace mRNA tech from basics to bedside: nucleoside-modified mRNA tames innate sensing and boosts translation; engineering across cap/UTRs/poly(A) plus purification optimizes stability and reduces immune noise. Lipid nanoparticles—especially ionizable lipids—are the enabling delivery system. Beyond infectious-disease vaccines, the field is moving toward on-demand/mobile manufacturing and immune-tolerance applications for autoimmunity/allergy, not just immune activation.

This podcast discusses how CRISPR gene-editing technology is revolutionizing healthcare by making personalized gene therapy a reality. From treating genetic disorders to unlocking precision medicine, CRISPR could transform the way we fight disease.

Performing successful CRISPR-Cas9 experiments isn’t just about cutting DNA—it requires precision, programming, and a deep understanding of both the technology and the biology behind it.That’s where CRISPR-GPT comes in: a DNA programming assistant built in Python for automating and optimizing gene-editing experiments.Think of it as your agentic co-pilot in the lab—helping design, analyze, and streamline CRISPR workflows, so you can focus on discovery and innovation.Join us as we explore how AI-driven automation is transforming the way we approach CRISPR, stem cells, and gene editing research.Reference article: https://www.nature.com/articles/s41551-025-01463-z.pdf

How reprogrammed T cells become living medicines. In clear, science-first episodes, we trace collection → engineering → infusion, highlight successes in B-cell cancers (CD19, BCMA), unpack risks (CRS, ICANS), and preview what’s next—off-the-shelf/allogeneic CARs, safety switches, and solid-tumor strategies. Subscribe for translational takeaways you can trust.

Organoids: Growing the Future of Medicine in Your Hand explores how mini-organs built from stem cells are reshaping drug discovery, disease modeling, and regenerative medicine today.